New and emerging combination therapies for esophageal cancer.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 3706320)

Published in Cancer Manag Res on June 27, 2013

Authors

Marcus W Wiedmann1, Joachim Mössner

Author Affiliations

1: Department of Internal Medicine I, St Mary's Hospital, Berlin, Germany ; Division of Gastroenterology and Rheumatology, Department of Medicine, Neurology and Dermatology, University Hospital of Leipzig, Leipzig, Germany.

Associated clinical trials:

Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer | NCT01216527

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | NCT00680901

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer (ST03) | NCT00450203

Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer (EXPAND) | NCT00678535

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | NCT01196390

REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer (REAL3) | NCT00824785

A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer (HELOISE) | NCT01450696

A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy (AIO-STO-0111) | NCT01248403

Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | NCT01107639

Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer | NCT00655876

MAGIC vs. CROSS Upper GI. ICORG 10-14, V3 | NCT01726452

Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy | NCT01243398

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer | NCT00861094

Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer | NCT00686114

Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer (POWER) | NCT01627379

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial | NCT01512589

Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma (ESCC-307PLAH) | NCT01752205

Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus (CONCORDE) | NCT01348217

A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma | NCT01591135

Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer | NCT01704690

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST) | NCT01285557

Articles cited by this

(truncated to the top 100)

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med (2006) 26.37

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (2010) 25.32

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77

Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med (2012) 15.43

Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med (2008) 12.97

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med (1996) 9.85

Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA (1999) 7.86

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol (2007) 6.08

Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol (2001) 6.07

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol (2011) 5.94

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol (2005) 5.40

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol (2005) 5.19

Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med (1997) 4.94

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol (2011) 4.77

Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol (2012) 4.48

A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol (2011) 4.22

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol (2008) 2.88

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol (2010) 2.83

Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol (2006) 2.61

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol (2005) 2.52

Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33

Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol (2006) 2.19

Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg (1993) 2.18

A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer (1994) 2.17

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol (2010) 2.10

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04

The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest (2001) 1.96

Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol (1999) 1.84

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol (2010) 1.83

Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg (2011) 1.82

Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol (1998) 1.80

Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer (1997) 1.60

A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology (1994) 1.55

A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol (2004) 1.53

Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer (1994) 1.52

Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol (2009) 1.46

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer (2009) 1.46

Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer (1993) 1.39

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer (2010) 1.39

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer (2010) 1.38

Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol (2007) 1.38

A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol (2004) 1.32

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer (2005) 1.31

A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res (2007) 1.28

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol (2010) 1.27

Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res (1998) 1.26

Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs (2010) 1.25

Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol (2005) 1.25

Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus (2006) 1.21

Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol (2010) 1.20

Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19

Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res (1996) 1.17

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol (2011) 1.16

A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol (2008) 1.16

Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer (2005) 1.15

Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer (2003) 1.13

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer (2010) 1.12

Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol (2009) 1.11

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol (1996) 1.10

Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res (2000) 1.10

Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg (2004) 1.08

First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer (2007) 1.08

A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol (2012) 1.06

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs (2006) 1.06

Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol (2010) 1.05

Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer (2011) 1.05

Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial. Ann Oncol (2012) 1.05

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol (2006) 1.03

Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study. Cancer (2012) 1.02

A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol (2007) 1.02

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol (2010) 1.01

Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs (2002) 1.01

Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol (2005) 1.00

Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol (2011) 1.00

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs (2010) 1.00

Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. Ann Oncol (2012) 1.00

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer (2011) 0.99

Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol (2009) 0.98

Current management of esophageal cancer. J Gastrointest Surg (2005) 0.95

Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg (2012) 0.95

Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol (2002) 0.94

A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol (2012) 0.94

Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol (2010) 0.94

A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res (2007) 0.90

Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol (2008) 0.89

Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Invest New Drugs (2008) 0.89

A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer. Hepatogastroenterology (2008) 0.89

A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol (2012) 0.89

Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy (2007) 0.87

VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. J Korean Med Sci (2011) 0.87

S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol (2011) 0.87

Prospective phase II study of neoadjuvant therapy with cisplatin, 5-fluorouracil, and bevacizumab for locally advanced resectable esophageal cancer. Onkologie (2012) 0.87

Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC Cancer (2011) 0.86

Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis Esophagus (2006) 0.86

Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol (2006) 0.86

[A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi (2003) 0.85

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer (2011) 0.84

Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol (2009) 0.82

Articles by these authors

(truncated to the top 100)

Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40

Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med (2009) 4.11

Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology (2003) 3.93

Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48

Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10

Vaccination coverage in immunosuppressed patients: results of a regional health services research study. Dtsch Arztebl Int (2011) 2.06

Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines. Gastroenterology (2003) 1.86

Chronic pancreatitis--definition, etiology, investigation and treatment. Dtsch Arztebl Int (2013) 1.82

Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis. Hum Mutat (2006) 1.80

CFTR, SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated? Gut (2012) 1.77

Diverse functional properties of Wilson disease ATP7B variants. Gastroenterology (2012) 1.61

Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer. Gastrointest Endosc (2003) 1.57

Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer (2006) 1.48

Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding. Pharmacoeconomics (2010) 1.42

Hereditary chronic pancreatitis. Orphanet J Rare Dis (2007) 1.40

Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer (2003) 1.35

Caroli's disease: liver resection and liver transplantation. Experience in 33 patients. Surgery (2005) 1.34

Mutational screening of patients with nonalcoholic chronic pancreatitis: identification of further trypsinogen variants. Am J Gastroenterol (2002) 1.24

Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol (2008) 1.18

Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene (2004) 1.16

Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug. J Biol Chem (2009) 1.12

Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc (2004) 1.08

Three CCAAT-boxes and a single cell cycle genes homology region (CHR) are the major regulating sites for transcription from the human cyclin B2 promoter. Gene (2003) 1.04

Gene conversion between functional trypsinogen genes PRSS1 and PRSS2 associated with chronic pancreatitis in a six-year-old girl. Hum Mutat (2005) 1.02

Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73. FEBS Lett (2002) 1.02

QTL mapping for genetic determinants of lipoprotein cholesterol levels in combined crosses of inbred mouse strains. J Lipid Res (2006) 1.02

Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. Scand J Gastroenterol (2011) 1.01

Interaction between trypsinogen isoforms in genetically determined pancreatitis: mutation E79K in cationic trypsin (PRSS1) causes increased transactivation of anionic trypsinogen (PRSS2). Hum Mutat (2004) 1.00

Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol (2007) 1.00

Hereditary chronic pancreatitis. Best Pract Res Clin Gastroenterol (2008) 0.97

Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs (2006) 0.95

Cyclin B1 transcription is enhanced by the p300 coactivator and regulated during the cell cycle by a CHR-dependent repression mechanism. FEBS Lett (2003) 0.93

Failure of screening or failure to screen? The screening behavior of patients with colorectal cancer in the Leipzig area. Dtsch Arztebl Int (2009) 0.93

Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study. Onkologie (2011) 0.92

Endoscopic treatment of duodenal obstruction due to a gallstone ("Bouveret's syndrome"). Ann Hepatol (2005) 0.91

Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. Biochem Biophys Res Commun (2007) 0.91

Gene expression of cyclin-dependent kinase subunit Cks2 is repressed by the tumor suppressor p53 but not by the related proteins p63 or p73. FEBS Lett (2007) 0.91

A single cell cycle genes homology region (CHR) controls cell cycle-dependent transcription of the cdc25C phosphatase gene and is able to cooperate with E2F or Sp1/3 sites. Nucleic Acids Res (2002) 0.91

TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr Metab Immune Disord Drug Targets (2009) 0.91

Novel bacteriochlorine for high tissue-penetration: photodynamic properties in human biliary tract cancer cells in vitro and in a mouse tumour model. J Photochem Photobiol B (2003) 0.91

Expression of mutated cationic trypsinogen reduces cellular viability in AR4-2J cells. Biochem Biophys Res Commun (2005) 0.90

Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. Curr Drug Targets (2010) 0.88

Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev (2013) 0.88

Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). J Hepatol (2002) 0.87

Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol (2005) 0.87

TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. Int J Cancer (2005) 0.87

Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73. Cell Cycle (2007) 0.87

Characterisation of a transgenic mouse expressing R122H human cationic trypsinogen. BMC Gastroenterol (2006) 0.86

Percutaneous transgastric irrigation drainage in combination with endoscopic necrosectomy in necrotizing pancreatitis (with videos). Gastrointest Endosc (2006) 0.86

BACE1 is a newly discovered protein secreted by the pancreas which cleaves enteropeptidase in vitro. JOP (2009) 0.85

Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. Am J Clin Oncol (2007) 0.85

Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev (2015) 0.85

Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PLoS One (2012) 0.84

Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer (2002) 0.84

Therapeutical concepts and results for Klatskin tumors. Dtsch Arztebl Int (2008) 0.83

Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. World J Gastroenterol (2006) 0.83

Lessons learned from excess mortality associated with Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in liver transplant recipients. Liver Transpl (2014) 0.83

Impact of capsule endoscopy on outcome in mid-intestinal bleeding: a multicentre cohort study in 285 patients. Eur J Gastroenterol Hepatol (2008) 0.83

Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance. World J Gastroenterol (2010) 0.83

Genetic and biochemical evidence for a functional role of BACE1 in the regulation of insulin mRNA expression. Obesity (Silver Spring) (2013) 0.82

Association of a lithogenic Abcg5/Abcg8 allele on Chromosome 17 (Lith9) with cholesterol gallstone formation in PERA/EiJ mice. Mamm Genome (2005) 0.82

Non-invasive diagnosis of von Meyenburg complexes. J Hepatol (2003) 0.82

Optimal timing of oral refeeding in mild acute pancreatitis: results of an open randomized multicenter trial. Pancreas (2010) 0.80

Genetic aspects of chronic pancreatitis. Med Sci Monit (2004) 0.79

Pre-study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis. BMC Gastroenterol (2013) 0.79

Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma. Anticancer Res (2011) 0.79

Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies. Curr Cancer Drug Targets (2011) 0.79

Transforming growth factor-beta-1 variants are not associated with chronic nonalcoholic pancreatitis. Pancreatology (2005) 0.79

Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors. Clin Med Insights Oncol (2012) 0.79

How effective is published medical education? Lancet (2004) 0.79

A common variant of PNPLA3 (p.I148M) is not associated with alcoholic chronic pancreatitis. PLoS One (2012) 0.79

Analysis of tumour necrosis factor alpha and interleukin 10 promotor variants in patients with chronic pancreatitis. Eur J Gastroenterol Hepatol (2003) 0.79

Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer? Anticancer Drugs (2003) 0.79

A pilot study of bendamustine in advanced bile duct cancer. Anticancer Drugs (2007) 0.78

Non-invasive evaluation of hepatic manifestation in Wilson disease with transient elastography, ARFI, and different fibrosis scores. Scand J Gastroenterol (2012) 0.78

Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev (2009) 0.78

The inverse starving test is not a suitable provocation test for Gilbert's syndrome. BMC Res Notes (2008) 0.78

Genetic analyses of heme oxygenase 1 (HMOX1) in different forms of pancreatitis. PLoS One (2012) 0.78

Rapid detection of mutations in Wilson disease gene ATP7B by DNA strip technology. Clin Chem Lab Med (2004) 0.78

Complete analysis of the human mesotrypsinogen gene (PRSS3) in patients with chronic pancreatitis. Pancreatology (2010) 0.78

Quality of life in patients with active ulcerative colitis treated with selective leukocyte apheresis. Scand J Gastroenterol (2007) 0.78

Effect of a structured psycho-oncological screening and treatment model on mental health in cancer patients (STEPPED CARE): study protocol for a cluster randomized controlled trial. Trials (2014) 0.78

Mutational analysis of the gene encoding the zymogen granule membrane glycoprotein 2 (GP2) in patients with chronic pancreatitis. Pancreas (2010) 0.77

A 79-year-old patient with yellow sputum. Gastroenterology (2010) 0.77

Genetic risk factors in chronic pancreatitis. J Gastroenterol (2002) 0.77

p8 Deficiency causes siderosis in spleens and lymphocyte apoptosis in acute pancreatitis. Pancreas (2014) 0.77

Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection. Eur J Gastroenterol Hepatol (2013) 0.77

Role of GB virus C in HIV-1-infected and hepatitis C virus-infected hemophiliac children and adolescents. J Acquir Immune Defic Syndr (2012) 0.77

Differences in bleeding behavior after endoscopic band ligation: a retrospective analysis. BMC Gastroenterol (2010) 0.77

ChroPac-trial: duodenum-preserving pancreatic head resection versus pancreatoduodenectomy for chronic pancreatitis. Trial protocol of a randomised controlled multicentre trial. Trials (2010) 0.77

Pitfall alveolar echinococcosis in non-endemic areas. Alveolar echinococcosis migrating northward. Ann Hepatol (2010) 0.76

Combined percutaneous transhepatic biliary drainage with port implantation for management of patients with malignant biliary obstruction. Gastrointest Endosc (2004) 0.76

Regression of pancreatic diabetes in chronic hereditary pancreatitis. Diabetes Care (2006) 0.76

The WayStation: the novel way for the collection of pancreatitis-associated mutations. Pancreatology (2004) 0.76

Noninvasive characterization of graft steatosis after liver transplantation. Scand J Gastroenterol (2014) 0.76

The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour. BMC Gastroenterol (2005) 0.76

Sequence analysis of the human tyrosylprotein sulfotransferase-2 gene in subjects with chronic pancreatitis. Pancreatology (2010) 0.76

In Reply. Dtsch Arztebl Int (2017) 0.75

Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther (2010) 0.75

A young traveller presenting with typhoid fever after oral vaccination: a case report. J Med Case Rep (2013) 0.75